A patient I started on semaglutide eight months ago came in for her three-month follow-up convinced the medication "wasn't working" because she had only lost six pounds. I pulled up her DEXA scan from baseline and the one we had just done. Her body fat percentage had dropped 4.2 points. Her visceral fat had dropped from a category-3 to a category-1 reading. Her lean mass was preserved. She had lost roughly twelve pounds of fat and gained six pounds of lean mass — a body composition shift most patients would describe as life-changing if they could see it. The scale was hiding the real story.
This is the conversation I have constantly with patients on medical weight loss programs. The expectations set by social media and direct-to-consumer GLP-1 marketing do not match how the physiology actually unfolds. Real medical weight loss moves on a timeline measured in months, not weeks, and the early markers that tell us it is working are not always the scale.
What "medical weight loss" actually is
The term gets used sloppily. In our medical weight loss program, it means a structured clinical workup that identifies the metabolic and hormonal drivers of the patient's weight, followed by an individualized intervention plan that may or may not include a GLP-1 receptor agonist, paired with body composition tracking and reassessment at defined intervals.
That is meaningfully different from "buy a compounded GLP-1 from the cheapest online pharmacy and hope for the best." I see patients all the time who came off that route, lost some weight initially, regained it within a year of stopping, and arrived in my office looking for a real answer. The medication is one tool. The program is the work that decides whether the tool fits, what dose your physiology actually needs, what else needs to be addressed simultaneously, and how to land the loss so it stays landed.
How GLP-1 medications work, mechanistically
GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide — mimic glucagon-like peptide-1, a gut hormone the body releases in response to food. The mechanism has three parts that all matter.
First, they slow gastric emptying. Food sits in the stomach longer, which means satiety signals stay active longer and the urge to eat between meals quiets down significantly.
Second, they act centrally on appetite-regulating circuits in the hypothalamus. Hunger gets quieter. The food noise that drives a lot of mid-life eating — the constant background thoughts about what to eat next — often disappears within the first few weeks. Patients consistently describe this as the most surprising part of the experience.
Third, they improve insulin sensitivity. This is the under-discussed mechanism. By improving how muscle and liver respond to insulin, GLP-1 receptor agonists pull patients out of the fat-storage state that insulin resistance traps them in. This is why patients who have been stuck for years can finally start losing fat on a GLP-1, even when their food intake has not changed dramatically.
Tirzepatide adds GIP receptor agonism on top of the GLP-1 effect, which is part of why it tends to produce larger losses in head-to-head comparisons — averaged across study populations, semaglutide produces about 15% body weight loss over 68 weeks; tirzepatide produces about 21% over similar timeframes. Individual response varies considerably, and the patients who get the best results are the ones whose program addresses everything else at the same time.
Why GLP-1 underperforms when it does
When a GLP-1 underperforms — and it does, in maybe 20-25% of patients — the reason is almost never the medication. It is usually one of these:
Untreated thyroid dysfunction. A patient with elevated reverse T3 or suboptimal free T3 has a basal metabolic rate that is fighting the medication. Treat the thyroid, the GLP-1 starts working.
Untreated sex hormone decline. A 52-year-old woman with estradiol below 30 and testosterone in the bottom 10% of range will not respond to GLP-1 the way a hormonally optimized patient will. Layer in hormone optimization and the response often unlocks.
Inadequate protein intake. GLP-1 medications suppress appetite — patients eat less of everything, including protein. If protein intake drops below about 0.8 to 1 gram per pound of lean body mass, the patient loses muscle alongside fat, basal metabolic rate falls, and weight loss stalls. This is the most common avoidable failure mode I see.
No resistance training. Same logic. Without a stimulus to preserve lean mass during caloric deficit, the body breaks down muscle for fuel. The scale moves but the body composition gets worse.
Insufficient sleep. Five hours of sleep a night will cap how much fat you lose on any program, GLP-1 included. Cortisol elevation from sleep restriction blocks lipolysis directly.
Wrong dose. Some patients need to titrate higher than the standard schedule. Others do better at a lower dose with longer time at each level. Conservative titration matched to individual response, rather than rigid escalation, produces better outcomes.
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
When I see a patient stalled on GLP-1, my first move is not to change the medication. It is to look at all five of these and find which one is the bottleneck.
How I structure the 90-day program
The structured phase of our medical weight loss program is 90 days. That is the window in which the workup, the initial intervention, the first reassessment, and the protocol refinement all happen. After day 90, patients either continue under maintenance or transition to a less-intensive monitoring schedule depending on their goals.
Days 1-30: workup and initiation. First visit covers comprehensive history. Lab panel ordered: full sex hormone panel, full thyroid panel, fasting insulin, HbA1c, complete metabolic panel, lipid panel including ApoB, hs-CRP, vitamin D, ferritin, B12. DEXA scan baseline if the patient is appropriate for body composition tracking. Lab review visit two weeks later to walk through the data and build the individualized plan. If GLP-1 is part of it, initiation happens here at the conservative starting dose. Adjacent interventions — hormone optimization, thyroid support, nutritional adjustments — get layered in deliberately rather than all at once.
Days 30-60: titration and adjustment. GLP-1 dose titrated based on tolerance and response, not the manufacturer's default schedule. Side effect management for the patients who need it — and most do, in the first few weeks. Protein and resistance training plan reinforced because this is when the muscle preservation conversation matters most. Adjacent therapies adjusted based on early markers.
Days 60-90: optimization and maintenance plan. Repeat labs and DEXA at day 90. Body composition data tells us whether what we are losing is fat (good) or fat plus muscle (problem to fix). The plan beyond day 90 gets built deliberately — this is the conversation most weight-loss programs skip, and it is the reason they have such high regain rates.
What the realistic timeline looks like, week by week
Expectations matter because patients who recognize success when it is happening stick with the program. Patients who expect dramatic scale movement in week three quit before the real changes show up.
- Weeks 1-4: appetite suppression starts within days of the first dose if the patient is responding. Weight loss in this window is usually 2-5 pounds. Most of it is fluid and reduced gut volume from slowed gastric emptying. Real fat loss has not started yet.
- Weeks 4-8: consistent weight loss of about 1-2 pounds per week typical for responders at therapeutic dose. Patients start to notice clothes fitting differently. Energy often improves. Side effects from titration usually fading by week 6.
- Weeks 8-12: body composition starts shifting visibly. Waist measurements drop more than the scale would predict because visceral fat tends to come off first. First DEXA reassessment at this point usually shows meaningful change even when the scale movement has been moderate.
- Months 3-6: the steady phase. About 1 pound of fat loss per week is realistic for most responders. Hormonal and thyroid interventions, if part of the plan, are now showing their effect on top of the GLP-1.
- Months 6-12: the loss curve flattens as the patient approaches their physiologic set point. Maintenance planning becomes the primary conversation.
The goal is sustained loss of 15-20% of body weight in the first year for most candidates. That number is not aspirational — it is the routine clinical outcome with a properly structured program.
What I look for at the candidacy conversation
Not everyone is a GLP-1 candidate, and not everyone who is a candidate needs to be on it forever. The candidacy assessment looks at:
- BMI and body composition (BMI alone is a crude screen — DEXA composition tells me much more)
- Current metabolic and hormonal status from the comprehensive lab panel
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome (absolute contraindications)
- Prior pancreatitis (relative contraindication, evaluated case by case)
- Gallbladder history (rapid weight loss is a gallstone risk; I want to know what we are working with)
- Realistic patient expectations about timeline, side effects, and the long-term framework
- Willingness to do the protein, resistance training, and sleep work that determines whether the loss is high-quality
Patients who are not GLP-1 candidates have other options. The full medical weight loss program includes hormone optimization, thyroid support where indicated, nutritional counseling, and structured movement guidance. GLP-1 is one lever among several, not the entire program.
I turn away patients at the candidacy stage when the request and the physiology do not match — the patient who wants to use GLP-1 to lose ten cosmetic pounds when their actual problem is muscle loss from inadequate protein, for example, is better served by addressing the protein and the training before adding a medication.
A concrete next step
If you are considering medical weight loss — whether you are GLP-1 curious, GLP-1 frustrated, or coming at this for the first time — the highest-yield first move is the comprehensive lab panel I described above plus a baseline DEXA if appropriate. Without those, any conversation about which protocol fits is a guess.
If you have already been on a GLP-1 elsewhere and the response has stalled or regained, bring whatever data you have: dosing history, duration, side effects, prior labs. The reasons GLP-1 underperforms are almost always addressable when you can see the full picture.
You can book a medical weight loss consultation through the online booking portal at either the Columbus or Warner Robins location. The first visit gathers the history and orders the labs. The second visit is the lab review and the actual plan. By that visit, we are working from your numbers, your goals, and your physiology — not the average patient's. That is what produces a result that lasts.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.